South Korean drug delivery specialist Inventage Lab has delivered the final formulation of its second long-acting injectable (LAI) drug candidate, IVL5007, to German pharma giant Boehringer Ingelheim. The milestone, achieved 1 year and 7 months after the first contract in September 2024, signals growing trust in Inventage's IVL-DrugFluidic platform and opens new supply-chain opportunities for contract formulation and manufacturing partners serving the global LAI market.
Deal expansion and timeline
Inventage Lab first partnered with Boehringer Ingelheim in September 2024 to co-develop an LAI formulation for a peptide-based drug candidate (IVL5006). By the first half of 2025, the companies had defined a target product profile and completed formulation research by July 2025. In November 2025, Boehringer extended the collaboration to a second peptide candidate, IVL5007, and Inventage delivered the final formulation in April 2026. Boehringer has now initiated internal and external evaluation of the delivered formulation.
Platform technology and collaboration model
Inventage Lab's IVL-DrugFluidic platform uses microfluidic-based microsphere manufacturing to formulate peptides and small molecules into long-acting injectables. Under the collaboration, Inventage applies the partner's drug candidate to its platform, develops candidate formulations, and supplies non-clinical trial samples. The partner focuses on efficacy and clinical studies, while Inventage handles formulation and process development. Indications, duration of effect, and contract size remain undisclosed at the partner's request.
Regulatory and channel signals
The expansion from one to two drug candidates within 14 months of the first contract indicates strong confidence in Inventage's platform. The collaboration may progress through non-clinical sample supply, joint clinical development, clinical-grade manufacturing, and global commercial supply agreements. Post-commercialization, a separate contract could enable platform technology transfer for manufacturing. Inventage has also secured GMP manufacturing capacity by acquiring KOSDAQ-listed Quratis in March 2025 and signed an MOU with a European pharma company to establish its manufacturing platform in Europe.
Sourcing context
For overseas importers, distributors, and clinic buyers, this development highlights the growing demand for long-acting injectable formulations in aesthetic and therapeutic segments. Inventage Lab's platform offers a scalable, GMP-compliant solution for partners seeking to outsource formulation and manufacturing of LAI products. The company's dual-track strategy—acquiring domestic GMP capacity and pursuing European manufacturing partnerships—positions it as a reliable contract development and manufacturing organization (CDMO) for global LAI supply chains.
Source: Read the original report | Published: June 02, 2026